Archives of Industrial Biotechnology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (629)348-3199

Short Communication - Archives of Industrial Biotechnology (2024) Volume 8, Issue 5

CRISPR technology: Revolutionizing genetic engineering and disease treatment

Joanna Golian *

Department of Microbiology, Stockholm University, Sweden

*Corresponding Author:
Joanna Golian
Department of Biotechnology, University of Zaragoza, Spain
E-mail: joannagolian@gmail.com < /dd>

Received: 01-Oct-2024, Manuscript No. AAAIB-24-148725; Editor assigned: 02-Oct-2024, PreQC No AAAIB-24-148725 (PQ) Reviewed:15-Oct-2024, QC No. AAAIB-24-148725 Revised:22-Oct-2024, Manuscript No. AAAIB-24-148725 (R); Published:28-Oct-2024, DOI:10.35841/aaaib-8.5.230

Citation: Golian J. CRISPR technology: Revolutionizing genetic engineering and disease treatment. Arch Ind Biot. 2024;8(5):230

Visit for more related articles at Archives of Industrial Biotechnology

Introduction

In recent years, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has emerged as one of the most significant breakthroughs in genetic engineering, offering unprecedented precision and efficiency in genome editing. The power of CRISPR lies in its ability to target and modify specific sections of DNA, leading to groundbreaking applications in a variety of fields, particularly in disease treatment and biomedical research. This article explores how CRISPR technology is revolutionizing genetic engineering and shaping the future of medicine [1].

CRISPR technology was adapted from a natural defense mechanism found in bacteria, where it is used to recognize and cut the DNA of invading viruses. The system involves two key components: a guide RNA (gRNA) that directs the CRISPR-associated protein (Cas9) to the target DNA sequence and the Cas9 protein itself, which acts as molecular scissors to cut the DNA at the desired location. Once the DNA is cut, the cell’s natural repair mechanisms can either introduce new genetic material or disrupt the gene function, enabling precise genetic modifications [2].

The ease of designing guide RNAs and the high specificity of the system have made CRISPR an ideal tool for genetic engineering, surpassing older techniques in both accuracy and cost-effectiveness. One of the most exciting applications of CRISPR is in the field of gene therapy, where it can be used to correct genetic mutations that cause disease. For instance, CRISPR has shown promise in treating genetic disorders like cystic fibrosis, sickle cell anemia, and muscular dystrophy by targeting and repairing the faulty genes responsible for these conditions [3].

CRISPR is also being used to develop genetically modified crops that are more resistant to pests, diseases, and environmental stresses. This has the potential to significantly improve food security, especially in regions affected by climate change [4].

In synthetic biology, CRISPR is used to engineer organisms with new traits or functions. For example, researchers are exploring the use of CRISPR to create bioengineered microorganisms that can produce biofuels or biodegradable plastics, offering sustainable alternatives to traditional industrial processes [5].

CRISPR technology has made it easier to create animal models of human diseases, which are crucial for studying the underlying mechanisms of diseases and testing new treatments. This has accelerated research in fields such as cancer, neurodegenerative diseases, and infectious diseases [6].

The potential of CRISPR in disease treatment is perhaps the most transformative aspect of the technology. Researchers have already demonstrated its effectiveness in preclinical models for treating a variety of diseases. In diseases caused by single-gene mutations, such as Huntington’s disease and Duchenne muscular dystrophy, CRISPR can be used to correct the mutation at its source. Early trials in humans, such as those targeting sickle cell anemia, have shown promising results, with patients experiencing significant improvement in symptoms [7].

CRISPR is being explored as a tool to enhance cancer immunotherapy. By editing the genes of immune cells (such as T-cells), CRISPR can boost the immune system’s ability to recognize and attack cancer cells. Clinical trials are underway to assess the safety and efficacy of CRISPR-based treatments for certain types of cancer, including leukemia and lymphoma [8].

CRISPR offers a novel approach to combating viral infections. Researchers are investigating the use of CRISPR to target and destroy viral DNA in cells infected with viruses such as HIV and hepatitis B. This could lead to potential cures for these chronic infections, which currently have no definitive cure [9].

CRISPR-based therapies are also being developed to treat inherited eye disorders such as Leber congenital amaurosis, a form of blindness caused by a genetic mutation. In 2020, the first clinical trial using CRISPR to directly edit genes inside the human body began, targeting this specific condition [10].

Conclusion

CRISPR technology represents a new frontier in genetic engineering and biomedical research. Its capacity to precisely and efficiently edit DNA holds immense promise for treating genetic diseases, improving agricultural practices, and advancing scientific knowledge. As researchers continue to explore its applications and refine its safety, CRISPR could transform the future of medicine, offering hope for cures to some of the most challenging diseases and redefining the limits of genetic modification.

References

  1. Peleg AY, Seifert H, Paterson DL et al. Acinetobacter baumannii: Emergence of a successful pathogen. Clin. Microbiol. 2008;21:538-82.

    2. Indexed at, Google Scholar, Cross Ref

  2. Falagas ME, Rafailidis PI, et al. Attributable mortality of Acinetobacter baumannii: No longer a controversial issue. Crit Care 2007;11:134.

    3. Indexed at, Google Scholar, Cross Ref

  3. Oly-Guillou ML. Clinical Impact and Pathogenicity of Acinetobacter. Clin Microbiol Infect. 2005;11:868-73.

    4. Indexed at, Google Scholar, Cross Ref

  4. Bragoszewska E, Pastuszka JS. Influence of meteorological factors on the level and characteristics of culturable bacteria in the air in Gliwice, Upper Silesia (Poland). Aerobiologia. 2018;34:241-255.

    5. Indexed at, Google Scholar, Cross Ref

  5. Jaber LR, Salem NM. Endophytes colonization of squash by the fungal entomopathogen Beauveria bassiana (Ascomycota: Hypocrites) for managing zucchini yellow mosaic virus in cucurbits.Bio controls Sci Technol. 2014;24:1096-1109.

    6. Indexed at, Google Scholar, Cross Ref

  6. Kiarie S, Nyasani JO, Gohole LS, et al. Impact of fungal endophyte colonization of maize (Zea Mays L.) on induced resistance to thrips- and aphid-transmitted viruses. Plants. 2020;9:416.

    7. Indexed at, Google Scholar, Cross Ref

  7. Van Leeuwen T, Tirry L, Yamamoto A, et al. The economic importance of acaricides in the control of phytophagous mites and an update on recent acaricide mode of action research. Pestic Biochem Physiol. 2015;121:12-21.

    8. Indexed at, Google Scholar, Cross Ref

  8. Sebastian J, Dominguez KV, Brar SK, et al. Fumaric acid production using alternate fermentation mode by immobilized Rhizopus oryzae-a greener production strategy. Chemosphere. 2021;281:130858.

    9. Indexed at, Google Scholar, Cross Ref

  9. Sasidharan S, Saud agar P, Leishmaniasis: Where are we and where are we heading?Parasitol Res. 2021;12(4):1541-54.

    10. Indexed at, Google Scholar, Cross Ref

  10. Lago JHG, Chaves MH, Ayres MCC, et al. Evaluation of antifungal and DNA-damaging activities of alkaloids from branches of Porcelain macrocarpa. Planta Med. 2007;73(3):292-95.

    11. Indexed at, Google Scholar, Cross Ref

Get the App